Oncolys BioPharma FY26 H1 operating loss narrows to JPY 767 million; net sales more than double to JPY 503 million

Reuters2026/08/07 05:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Oncolys BioPharma posted net sales of JPY 503.09 million for the six months ended June 30, 2026, up 1,662.4% year over year.
Operating loss narrowed to JPY 767.61 million from JPY 1.27 billion a year earlier.
Net loss improved to JPY 762.15 million; basic loss per share narrowed to JPY 26.03.
OBP-301 won full marketing approval in Japan for esophageal cancer in June; its drug price was set at JPY 3,102,489 per dose.
Oncolys withheld a full-year forecast, citing earnings volatility tied to milestone payments, OBP-301 rollout, and alliance terms.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolys BioPharma Inc. published the original content used to generate this news brief on August 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Oncolys BioPharma FY26 H1 operating loss narrows to JPY 767 million; net sales more than double to JPY 503 million

You may also like

Crypto prices